View Archive »
About The Cover
The cover for issue 93 of Oncotarget features Figure 2, "Comparison of overall survival (OS) and leukemia-free survival (LFS) between CloB2A1 and CloB2A2 sub-groups," by Le Bourgeois, et al.
|
|
Table of Contents
Editorial
|
| CLAGM with doseescalated mitoxantrone for adults with acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.26383
|
| 36543-36544 |
|
| Cancer immunotherapy: Moving beyond checkpoint inhibition |
|
https://doi.org/10.18632/oncotarget.26384
|
| 36545-36546 |
|
| Genomic biomarker of checkpoint efficacy highways for precision medicine in lung cancer |
|
https://doi.org/10.18632/oncotarget.26389
|
| 36547-36548 |
|
| Using genomics to better define highrisk MGUS/SMM patients |
|
https://doi.org/10.18632/oncotarget.26390
|
| 36549-36550 |
Research Papers
|
| IGFBP2 is a potential biomarker in acute kidney injury AKI and resveratrolloaded nanoparticles prevent AKI |
|
https://doi.org/10.18632/oncotarget.25663
|
| 36551-36560 |
|
| Significance of intranuclear angiotensinII type 2 receptor in oral squamous cell carcinoma |
|
https://doi.org/10.18632/oncotarget.26337
|
| 36561-36574 |
|
| Preoperative diffusionweighted magnetic resonance imaging and intraoperative frozen sections for predicting the tumor grade in endometrioid endometrial cancer |
|
https://doi.org/10.18632/oncotarget.26366
|
| 36575-36584 |
|
| Cotreatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression |
|
https://doi.org/10.18632/oncotarget.26379
|
| 36585-36602 |
|
| Clofarabine/busulfanbased reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGMTC |
|
https://doi.org/10.18632/oncotarget.26391
|
| 36603-36612 |
|
| Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.26400
|
| 36613-36624 |
|
| Metaanalysis of the likelihood of FOXC1 expression in early and latestage tumors |
|
https://doi.org/10.18632/oncotarget.26358
|
| 36625-36630 |
Reviews
|
| Tumour treating fields in a combinational therapeutic approach |
|
https://doi.org/10.18632/oncotarget.26344
|
| 36631-36644 |
Corrections
|
| Correction: The antirheumatic drug leflunomide synergizes with MEK inhibition to suppress melanoma growth |
|
https://doi.org/10.18632/oncotarget.26415
|
| 36645-36645 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
